October 11, 2023 07:15 AM EDT
R&D

No­vo stops late-stage kid­ney tri­al for semaglu­tide ear­ly for ef­fi­ca­cy, da­ta com­ing in 2024

Katherine Lewin

News Reporter

No­vo Nordisk is stop­ping a Phase II­Ib kid­ney-fo­cused tri­al for its GLP-1 drug semaglu­tide ear­ly for ef­fi­ca­cy, the com­pa­ny an­nounced Tues­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

No­var­tis claims best earn­ings in years, val­i­dat­ing shift to pure-play strat­e­gy

Roche sep­a­rates CFO, in­for­mat­ics posts; Lil­ly ex­ecs land at Kail­era, Neu­ro­crine

Ver­tex's non-opi­oid pain drug is ap­proved by FDA, bring­ing first of new class to mar­ket

Fri­day IPO dou­ble­head­er from Maze and Met­sera brings life to biotech de­buts

Ab­b­Vie rais­es Skyrizi and Rin­voq es­ti­mates, pre­dicts $31B in 2027 sales

sponsored

Why the pre­mier re­cruit­ment agency in the world is giv­ing up re­cruit­ing, and spon­sors should, too

A service from the Financial Times